文献速递肾移植

肾移植中的细胞治疗:聚焦调节性T细胞

Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells.
PubMed 文献 · J Am Soc Nephrol · 2017-05-02

本文综述了调节性T细胞(Treg)治疗在肾移植中的免疫学基础与技术挑战,包括Treg亚群选择、体外扩增方法、输注数量与时机及输注后患者管理,旨在减少非特异性免疫抑制剂的全身与肾脏毒性。

要点

  • Treg治疗可减少肾移植后非特异性免疫抑制剂的毒性负担
  • Treg亚群选择、扩增方法、输注数量与时机是关键技术挑战
  • 输注Treg后需关注患者的后续管理

核心结论

  • 使用患者自身抑制性调节性T细胞是减少肾移植后非特异性免疫抑制负担的有吸引力的生物学方法。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 综述了Treg治疗的免疫学基础及开发成功细胞治疗的技术挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Renal transplantation is the renal replacement modality of choice for suitable candidates with advanced CKD or ESRD. Prevention of rejection, however, requires treatment with nonspecific pharmacologic immunosuppressants that carry both systemic and nephrologic toxicities. Use of a patient's own suppressive regulatory T cells (Tregs) is an attractive biologic approach to reduce this burden. Here, we review the immunologic underpinnings of Treg therapy and technical challenges to developing successful cell therapy. These issues include the selection of appropriate Treg subsets, ex vivo Treg expansion approaches, how many Tregs to administer and when, and how to care for patients after Treg administration.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zwang NA, Leventhal JR. Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells. J Am Soc Nephrol. 2017. PMID: 28465379. doi:10.1681/ASN.2016111206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。